AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
224.21
-1.38 (-0.61%)
As of 11:42AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close225.59
Open223.68
Bid224.14 x 800
Ask224.36 x 3000
Day's Range221.20 - 224.93
52 Week Range166.30 - 244.99
Volume947,788
Avg. Volume2,290,260
Market Cap133.222B
Beta (5Y Monthly)1.12
PE Ratio (TTM)17.25
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield6.40 (2.72%)
Ex-Dividend DateFeb 12, 2020
1y Target EstN/A
All
News
Press Releases
  • Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences
    PR Newswire

    Free "LabXchange" Science Education Accelerator Launched By Amgen Foundation And Harvard's Faculty Of Arts And Sciences

    The Amgen Foundation and the Faculty of Arts and Sciences at Harvard University (Harvard FAS) today announced the global launch of LabXchange™, a free online science education platform that provides users with access to personalized instruction, virtual lab experiences and networking opportunities across the global scientific community. LabXchange is purpose-built to drive more inclusion in the scientific process and spark collaboration to build creative, team-based approaches to real-world problems.

  • PR Newswire

    Amgen Announces Global Diagnostic Collaborations To Expand Molecular Testing For Patients With Non-Small Cell Lung Cancer

    Amgen (NASDAQ: AMGN) today announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510. AMG 510 is the first KRASG12C inhibitor to advance to the clinic for investigation in treatment of multiple tumor types. KRAS G12C is one of the most frequently mutated oncogenes in human cancers. The agreements with both companies will initially focus on CDx tests for non-small cell lung cancer (NSCLC) but allow for further development of the diagnostic tests for Amgen's other oncology clinical development programs.

  • PR Newswire

    Amgen To Present At The 38th Annual J.P. Morgan Healthcare Conference

    Amgen (NASDAQ:AMGN) will present at the 38th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 14, 2020, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.

  • PR Newswire

    Amgen To Present At The Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference

    Amgen (NASDAQ:AMGN) will present via video conference at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference at 1 p.m. PT on Thursday, Jan. 9, 2020. Robert A. Bradway, chairman and chief executive officer at Amgen, and Peter H. Griffith, executive vice president and chief financial officer at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.

  • GlobeNewswire

    BeiGene Announces Closing of Amgen Global Strategic Oncology Collaboration and Equity Investment

    BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that, following approval by its shareholders and satisfaction of other closing conditions, the global strategic oncology collaboration with Amgen (AMGN), previously announced on October 31, 2019, has become effective and Amgen has completed its purchase of an approximately 20.5% equity stake in BeiGene. Under the terms of the collaboration, BeiGene will assume responsibility for the commercialization and development in China of Amgen’s three oncology medicines, XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) that have been approved or filed in China.

  • PR Newswire

    Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China

    Amgen (NASDAQ: AMGN) today announced the successful closing of the transaction to enter into a strategic collaboration with BeiGene that will significantly accelerate Amgen's plans to expand its oncology presence in China, the world's second-largest pharmaceutical market. BeiGene is a commercial-stage research-based oncology company with an established and highly experienced team in China, including an approximately 900-person commercial organization and an approximately 600-person clinical development organization.

  • PR Newswire

    Amgen And Allergan Submit Biologics License Application For ABP 798, Biosimilar Candidate To Rituxan® (rituximab), To U.S. Food And Drug Administration

    Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan® (rituximab). Amgen and Allergan are collaborating on four oncology biosimilar medicines, two of which have already been approved by the FDA.

  • PR Newswire

    European Commission Approves EVENITY® (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

    Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced that the European Commission (EC) has granted marketing authorization for EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture. EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).

  • PR Newswire

    Amgen Announces 10% Increase In 2020 First Quarter Dividend

    Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.60 per share dividend for the first quarter of 2020. The dividend will be paid on March 6, 2020, to all stockholders of record as of the close of business on Feb. 14, 2020. This represents a 10% increase from that paid in each of the previous four quarters. Since the Company initiated a dividend in 2011, it has increased the dividend each year with the quarterly payout in 2019 up more than five-fold since its inception.

  • PR Newswire

    Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting

    Amgen (NASDAQ:AMGN) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma. The data will be presented in a late-breaking abstract session at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition.

  • Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease
    PR Newswire

    Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease

    Scientists at deCODE genetics and colleagues from the National University Hospital in Iceland today present the largest-scale study to date of the role and public health impact of Lipoprotein(a) as a risk factor for cardiovascular disease. The study appears today in the online edition of the Journal of the American College of Cardiology.

  • PR Newswire

    Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub

    Amgen (NASDAQ:AMGN) today announced the signing of a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental Design (LEED) candidate facility in the Gateway of Pacific campus development in South San Francisco. The new location, currently under construction at Oyster Point, will house Amgen's Bay Area employees focused on cardiometabolic, inflammation and oncology, research.

  • PR Newswire

    FDA Approves Amgen's AVSOLA™ (infliximab-axxq), For The Same Indications As Remicade® (infliximab)

    Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab): for the treatment of moderate-to-severe rheumatoid arthritis (RA), moderate-to-severe Crohn's Disease (CD) in the adult and pediatric population, moderate-to-severe ulcerative colitis (UC) in the adult and pediatric population, chronic severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

  • PR Newswire

    Amgen Completes Acquisition Of Otezla® (apremilast)

    THOUSAND OAKS, Calif., Nov. 21, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (BMY), which was completed on Nov. 20. Otezla is an important treatment in the post-topical, pre-biologic segment in its approved indications in the U.S., including the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease.

  • GlobeNewswire

    New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function

    THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France,, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier announced that new results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), will be presented today at the American Heart Association’s (AHA) Scientific Sessions 2019 in Philadelphia. In patients with HFrEF treated with omecamtiv mecarbil, in addition to previously reported improvements in cardiac contractility measures (including systolic function, or pumping action of the heart), measures of diastolic function were not different from placebo and, for some measures, trended towards improvement.

  • PR Newswire

    New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function

    THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Nov. 18, 2019 /PRNewswire/ -- Amgen (AMGN), Cytokinetics, Incorporated (CYTK) and Servier announced that new results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), will be presented today at the American Heart Association's (AHA) Scientific Sessions 2019 in Philadelphia. In patients with HFrEF treated with omecamtiv mecarbil, in addition to previously reported improvements in cardiac contractility measures (including systolic function, or pumping action of the heart), measures of diastolic function were not different from placebo and, for some measures, trended towards improvement.

  • PR Newswire

    Amgen Announces New FOURIER Analysis Showing Benefit Of Repatha® (evolocumab) In High-Risk Patients Who Have Experienced A Recent Heart Attack

    THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes (FOURIER) study that evaluates the effectiveness of Repatha in patients who have suffered a recent myocardial infarction (MI). In the analysis, the risk reduction for experiencing a heart attack, stroke or CV death, in Repatha-treated patients treated within one year post MI was 25% compared to 15% in those patients with a more distant MI.

  • PR Newswire

    Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

    THOUSAND OAKS, Calif., Nov. 15, 2019 /PRNewswire/ -- Amgen (AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) today announced plans to initiate the Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9 inhibitors (cvMOBIUS) study—the first large-scale real-world study to assess lipid management and the impact of PCSK9 inhibitors on cardiovascular (CV) outcomes in clinical practice. While there is strong evidence demonstrating the efficacy of PCSK9 inhibitors from various randomized clinical trial studies, there is less information on the effectiveness of these medicines on cardiovascular outcomes in real-world practice.

  • PR Newswire

    Amgen Highlights Data To Be Presented At AHA 2019 Across Cardiovascular Portfolio

    THOUSAND OAKS, Calif., Nov. 11, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that new data from its cardiovascular portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2019 in Philadelphia, Nov. 16-18. This includes new clinical and real-world studies that provide further evidence of the benefits of intensive lipid-lowering therapy with Repatha® (evolocumab) as well as new data for omecamtiv mecarbil, a novel selective cardiac myosin activator being developed for the treatment of heart failure with reduced ejection fraction (HFrEF). "The Amgen clinical and real-world data being presented at AHA highlights our ongoing commitment to further the cardiovascular community's understanding of Repatha's role in lowering high LDL-C, one of the most important modifiable risk factors associated with an increased risk of heart attack,"1 said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • PR Newswire

    Amgen To Present At The 28th Annual Credit Suisse Healthcare Conference

    THOUSAND OAKS, Calif. , Nov. 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 28 th Annual Credit Suisse Healthcare Conference at 9:45 a.m. MT on Tuesday , Nov. 12, 2019, in Scottsdale, ...

  • GlobeNewswire

    BeiGene Announces Global Strategic Oncology Collaboration with Amgen

    • Companies to Collaborate on the Commercialization of XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) in China  • Companies to Jointly Develop 20.

  • PR Newswire

    Amgen Enters Into Strategic Collaboration With BeiGene To Expand Oncology Presence In China

    Amgen to Acquire 20.5% Stake in BeiGene for Approximately $2.7 Billion in Cash BeiGene to Commercialize XGEVA® (denosumab), KYPROLIS® (carfilzomib) and BLINCYTO® (blinatumomab) in China Companies to Collaborate ...

  • The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature
    PR Newswire

    The Discovery Of Amgen's Novel Investigational KRAS(G12C) Inhibitor AMG 510 Published In Nature

    THOUSAND OAKS, Calif., Oct. 30, 2019 /PRNewswire/ -- Amgen (AMGN) today announced a publication in Nature unveiling the discovery of AMG 510, a small molecule inhibitor of KRASG12C being investigated as a treatment for a variety of solid tumors with KRAS G12C mutation. Titled "The Clinical KRASG12C Inhibitor AMG 510 Drives Anti-Tumor Immunity," the paper highlights novel structural insights that led to the discovery of AMG 510, the preclinical evidence of AMG 510 activity, its potential ability to induce tumor-cell killing as both a monotherapy and in combination with other therapies, and its impact on the immune system that may render tumor cells particularly sensitive to immunotherapy. "We are pleased to share how our team of scientists at Amgen were the first to exploit the previously hidden groove on the protein surface to finally identify a potential drug against this important oncogenic protein," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  • PR Newswire

    Amgen Reports Third Quarter 2019 Financial Results

    THOUSAND OAKS, Calif. , Oct. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the third quarter of 2019. Key results include: Total revenues decreased 3% to $5.7 billion ...

  • PR Newswire

    Amgen Announces Webcast of 2019 Third Quarter Financial Results

    THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its third quarter financial results on Tuesday, Oct. 29, 2019, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.